Genmab Cuts 2026 Revenue Estimate to $4.31B, Eyes 43% Upside
Genmab AS is projected to report Q1 2026 revenue of $0.89 billion and EPS of $0.33 after analysts lowered full-year 2026 revenue estimates by $0.07 billion to $4.31 billion and EPS to $1.22. The $38.88 average price target implies 43% upside from $27.22, backed by a 1.6 ‘Outperform’ consensus.
1. Q1 2026 Earnings Outlook
Genmab AS will report Q1 2026 results on May 7, with analysts forecasting $0.89 billion in revenue and $0.33 in EPS, reflecting expectations for continued growth in antibody therapeutics.
2. Full-Year Estimate Revisions
Over the past 90 days, full-year 2026 revenue estimates were lowered from $4.38 billion to $4.31 billion and EPS projections trimmed from $1.25 to $1.22 per share, signaling tempered optimism on near-term performance.
3. Analyst Price Targets and Ratings
Thirteen analysts set an average one-year price target of $38.88 (high $48.00, low $30.50), implying roughly 43% upside, while a GF valuation of $45.73 suggests 68% potential gains; consensus rating stands at 1.6 (Outperform).
4. Historical Q4 2025 Performance
In Q4 2025 Genmab reported $1.06 billion in revenue (0.1% miss) and $0.04 EPS (89% miss), triggering a 0.1% one-day stock decline and highlighting execution challenges in its antibody portfolio.